All News

The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.

The collaboration highlights how pharmaceutical companies are pairing capital and global infrastructure with platform technologies that deliver differentiated dosing and durability.

The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.

How demand-driven development will help new products be more successful.

DTP programs are redefining the manufacturer’s access operating model.

Teva’s VP of US innovative medicines marketing discusses the origins of the company’s new campaign featuring comedian Will Forte.

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.

Public Citizen’s lawsuit highlights broader concerns over government transparency and oversight in pharmaceutical policy.

Tenpoint Therapeutics has paired FDA's approval for Yuvezzi with $235 million in new financing to support its U.S. launch and broader push into age-related vision loss.

In the final part of his conversation with Pharmaceutical Executive, Clay Siegall (president and CEO of Immunome) details the next steps for his upcoming medication.

The preservative, which contains a form of Mercury, has long been the target of anti-vaccine groups, despite studies demonstrating its safety.

EVERSANA president Greg Skalicky continues the conversation, providing details about the commercialization strategy.

As precision medicine shifts from promise to practice, true patient impact will depend less on standalone drugs and more on whether pharma, MedTech, and diagnostics can finally converge to build integrated systems of care.

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.

The research collaboration will leverage Seamless’ recombinase technology to develop programmable treatments for hearing loss.

The collaboration with Qilu extends Insilico’s application of generative AI into cardiometabolic disease drug discovery, with both companies aiming to advance candidates from early design through development under a shared strategic framework.

The FDA's approval is based on results from the Phase III CEPHEUS study, showing deeper and more durable responses compared with standard therapy.

Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.

Precigen's president and CEO discusses the recent launch of Papzimeos.

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management through real-world evidence, and differentiation as ADC pipelines become increasingly crowded.

In today’s Pharmaceutical Executive Daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reassess compliance risks tied to unmanaged tail spend, and Boehringer Ingelheim enters a $1 billion collaboration with Simcere to advance bispecific antibody research.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Taking a more strategic, data-driven approach to tail spend can transform procurement from a fragmented cost center into a source of compliance strength, operational efficiency, and greater supply chain confidence.

The collaboration agreement strengthens Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.

Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.